This is not the first occasion that pharmaceutical companies have experienced enforcement action from the competition authorities. In June 2013 the European Commission fined Danish pharmaceutical company Lundbeck €93.8 million, and other pharmaceutical companies (including Alpharma) €52.2 million, for preventing the market entry of competing generic versions of Lundbeck's anti-depressant citalopram. In the December of 2013 the European Commission again took action against pharmaceutical companies. On that occasion Johnson & Johnson and Novartis were fined €10,798,000 and €5,493,000 respectively for coming to an agreement that delayed the market entry of a generic version of the painkiller fentanyl.